We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Injectable Spacer Reduces Radiotherapy Consequences

By MedImaging International staff writers
Posted on 24 Jun 2015
A novel spacer separates the rectum from the prostate during radiotherapy (RT), potentially reducing the risk of adjacent organ-at-risk (OAR) injury.

The SpaceOAR system is a temporary injectable gel that protects the rectum in men undergoing RT for prostate cancer. The hydrogel, which is created from a mixture of two separate syringes, is injected through the perineum, guided by transrectal ultrasound. The material flows into the space between the prostate and the rectum and expands within ten seconds, filling the space and reducing rectum radiation during prostate RT. The hydrogel remains in place for three months, and is then liquefied and absorbed, leaving nothing behind.

Image: The SpaceOAR system benefits (Photo courtesy of Augmenix).
Image: The SpaceOAR system benefits (Photo courtesy of Augmenix).

Because the prostate gland is located close to the bladder and rectum, it is important for RT to be tightly focused on the prostate to avoid serious side effects to surrounding organs, such as bleeding, diarrhea, and pain. Shielding the rectum from radiation also permits dose escalation and hypo-fractionation, resulting in more prostate radiation, improved cancer kill rates, and fewer radiation treatment sessions. The SpaceOAR system is a product of Augmenix (Waltham, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“For years, hydrogel products have been used safely to protect the most sensitive parts of the body as sealants and adhesion barriers, and now prostate cancer patients will also be able to benefit,” said John Pedersen, CEO of Augmenix. “FDA clearance of the SpaceOAR System represents a significant development in advancing the safety, precision, and flexibility with which prostate cancer radiotherapy can be delivered.”

Related Links:

Augmenix



Multi-Use Ultrasound Table
Clinton
40/80-Slice CT System
uCT 528
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Ultra-Flat DR Detector
meX+1717SCC

Latest Radiography News

AI Detects Fatty Liver Disease from Chest X-Rays
24 Jun 2015  |   Radiography

AI Detects Hidden Heart Disease in Existing CT Chest Scans
24 Jun 2015  |   Radiography

Ultra-Lightweight AI Model Runs Without GPU to Break Barriers in Lung Cancer Diagnosis
24 Jun 2015  |   Radiography